ALVO Estados financieros: Análisis de Alvotech SA AI



Finanzas

ALVO Financiero

Alvotech SA

$3.26

1.87%

$0.05

Al cierre: May 08, 16:00:00 GMT-4

$3.4

4.29%

$0.14

Mercado Previo: May 11, 09:12:02 GMT-4

Visión general Pronóstico Ganando Dividendos Finanzas

Estadísticas clave

Cierre Anterior

$3.2

Precio de apertura

$3.21

Rango del día

$3.17 - $3.4

Rango de 52 semanas

$3.03 - $11.85

Volumen

469.9K

Volumen promedio

535.2K

Rendimiento de dividendos

EPS (TTM)

0.05

Cap. de mercado

$1.0B

¿Qué es ALVO?

Alvotech is a biotechnology company, which engages in the development and manufacture of biosimilar medicines. The firm is focused on the development and manufacture of biosimilar medicines for patients globally. The company is engaged in developing a pipeline of monoclonal antibodies that target a variety of therapeutic areas including inflammatory diseases, oncology, and ophthalmology. The Company’s pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Its products pipeline includes AVT02, AVT04, AVT23, AVT03, AVT05, AVT06, AVT16, and AVT33. Its AVT02 is a monoclonal antibody and a biosimilar to Humira (adalimumab). AVT04 is a monoclonal antibody and a biosimilar candidate to Stelara (ustekinumab). The company has formed a network of strategic commercial partnerships to provide global reach and leverage expertise in markets that include the United States (U.S.), Europe, Japan, China, and other Asian countries and large parts of South America, Africa, and the Middle East.

Ingreso

Balance general

Flujo de efectivo

Anual

Trimestral

ALVO Ingreso

Resultados financieros en millones de dólares estadounidenses. El ejercicio fiscal es febrero - enero.

Breakdown	TTM	12/31/2025	09/30/2025	06/30/2025	03/31/2025	12/31/2024
Ingresos	588	168	113	173	132	153
Crecimiento de los Ingresos (YoY)	20%	10%	11%	-13%	267%	178%
Costo de los ingresos	235	61	35	73	65	80
Utilidad bruta	353	107	78	99	67	73
Venta, General y Administración	90	19	25	26	18	19
Investigación y Desarrollo	184	39	51	54	38	40
Gastos de Operación	275	59	77	81	56	59
Otras Ingresos (Gastos) No Operativos	--	--	--	--	--	--
Ingreso antes de impuestos	136	39	-6	9	93	-44
Gasto por Impuesto a la Renta	108	148	0	-22	-16	22
Ingreso Neto	27	-108	-5	32	109	-66
Crecimiento de la Utilidad Neta	-112%	64%	-55%	-51%	-150%	-76%
Acciones en Circulación (Diluidas)	287.85	287.85	300.01	289.81	313.37	286.47
Cambio de Acciones (YoY)	0%	0%	6%	13%	28%	26%
EPS (Diluido)	0.09	-0.37	-0.01	0.11	0.35	-0.23
Crecimiento de EPS	-111%	61%	-56.99%	-56%	-139%	-81%
Flujo de efectivo libre	-146	-78	-83	27	-10	-70
Flujo de efectivo libre por acción	--	--	--	--	--	--
Margen bruto	60.03%	63.69%	69.02%	57.22%	50.75%	47.71%
Margen de operación	13.26%	28.57%	0.88%	10.4%	7.57%	8.49%
Margen de beneficio	4.59%	-64.28%	-4.42%	18.49%	82.57%	-43.13%
Margen de flujo de caja libre	-24.82%	-46.42%	-73.45%	15.6%	-7.57%	-45.75%
EBITDA	115	58	11	26	18	21
Margen de EBITDA	19.55%	34.52%	9.73%	15.02%	13.63%	13.72%
D&A para EBITDA	37	10	10	8	8	8
EBIT	78	48	1	18	10	13
Margen de EBIT	13.26%	28.57%	0.88%	10.4%	7.57%	8.49%
Tasa de Impuesto Efectiva	79.41%	379.48%	0%	-244.44%	-17.2%	-50%

Follow-Up Questions

Alvotech SA의 주요 재무제표는 무엇인가요?



최신 재무제표(Form-10K)에 따르면, Alvotech SA의 총 자산은 $0이며, 순pérdida입니다.

ALVO의 주요 재무 비율은 무엇인가요?



Alvotech SA의 유동비율은 0이고, 순이익률은 0, 주당 매출은 $0입니다.

Alvotech SA의 매출은 부문 또는 지역별로 어떻게 나뉘나요?



El segmento de ingresos más grande es Alvotech SA, con unos ingresos de Biosimilar Medicines en el último informe de ganancias. En cuanto a la geografía, Europe es el mercado principal para Alvotech SA, con unos ingresos de 307,220,000.

Alvotech SA은 수익성이 있나요?



no, 최신 재무제표에 따르면 Alvotech SA의 순pérdida은 $0입니다.

Alvotech SA에 부채가 있나요?



no, Alvotech SA의 부채는 0입니다.

Alvotech SA의 발행 주식은 몇 주인가요?



Alvotech SA의 총 발행 주식은 0주입니다.

Alvotech SA (ALVO) Financiero

Gráfico del Precio de Acciones ALVO